Type 1 Diabetes TrialNet Clinical Network Hub

1 型糖尿病 TrialNet 临床网络中心

• 批准号: 9068911
• 负责人: CARLA J GREENBAUM
• 金额: $ 139.5万
• 依托单位: BENAROYA RESEARCH INST AT VIRGINIA MASON
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-07-31 至 2019-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9068911
• 关键词: Area; Chairperson; Clinical; Clinical Trials; Clinical Trials Network; Development Plans; Diabetes Mellitus; Fostering; Gap Junctions; Health; Health Personnel; Information Dissemination; Insulin-Dependent Diabetes Mellitus; International; Leadership; Participant; Pilot Projects; Prevention; Prevention trial; Process; Qualifying; Research; Research Institute; Research Personnel; Risk; Structure; Testing; Training; United States National Institutes of Health; clinical research site; cost; design; digital; experience; innovation; insulin dependent diabetes mellitus onset; outreach; prevent; screening

DESCRIPTION (provided by applicant): Diabetes TrialNet is an international clinical trial network aimed to delay or prevent the onset of type 1 diabetes. As described, the new Diabetes TrialNet structure will now include a Diabetes TrialNet Clinical Hub, the Director of which will be part of the TrialNet leadership team including representatives of the NIH, the TrialNet Coordinating Center, and TrialNet chairman. The Benaroya Research Institute (BRI) serves as a nexus of T1D research, and with decades of clinical trial experience in T1D prediction and prevention, Dr. Greenbaum is uniquely qualified to serve as the TrialNet Clinical Network Hub (HUB). This application describes our proposal to become the Diabetes TrialNet Clinical HUB. We focus on three areas; activities to (a) enhance risk screening and prevention trial recruitment, (b) support clinical trials, and (c) enhance clinical administration and include proposed pilot studies to test innovative ideas for increasing recruitment, retention, and cost efficiencies.

描述（由申请人提供）：Diabetes TrialNet 是一个国际临床试验网络，旨在延缓或预防 1 型糖尿病的发病。如上所述，新的糖尿病试验网结构现在将包括一个糖尿病试验网临床中心，其主任将是 TrialNet 领导团队的一部分，包括 NIH、TrialNet 协调中心和 TrialNet 主席的代表。贝纳罗亚研究所 (BRI) 是 T1D 研究的纽带，Greenbaum 博士在 T1D 预测和预防方面拥有数十年的临床试验经验，拥有担任 TrialNet 临床网络中心 (HUB) 的独特资格。该应用程序描述了我们成为糖尿病 TrialNet 临床中心的提议。我们专注于三个领域；开展以下活动：(a) 加强风险筛查和预防试验招募；(b) 支持临床试验；(c) 加强临床管理，并包括拟议的试点研究，以测试增加招募、保留和成本效率的创新想法。